

COMPANION BIOMARKERS IN DRUG DEVELOPMENT *(SAMPLE COPY, NOT FOR RESALE)*

Trends, Industry Participants, Product Overviews and Market Drivers



TABLE OF CONTENTS

1. Overview	13
1.1 Statement of Report	13
1.2 About This Report	13
1.3 Scope of the Report	13
1.4 Objectives	13
1.5 Methodology	15
1.6 Executive Summary	16
2. Introduction: Companion Diagnostics in Drug Development	19
2.1 Companion Diagnostics as Biomarkers	20
2.1.1 Potential Benefits of Biomarkers as Companion Diagnostics	22
2.2 Biomarkers in Different Phases of Drug Development	22
2.2.1 Drug Discovery and Development Process	22
2.2.2 Biomarkers in Drug Development	24
2.3 Drug Targets	24
2.3.1 Target Discovery Using Functional Genomics	26
2.3.2 Functional Genomics	26
2.3.3 Target Validation	28
2.3.3.1 Target Discovery	28
2.3.3.2 Lead Identification	28
2.3.4 Target and Biomarker Discovery	29
2.3.4.1 Biomarker Validation	29
2.4 Biomarkers in Drug Discovery, Development and Clinical Diagnostics	29
2.4.1 Role of Biomarkers in Drug Discovery, Preclinical, Clinical Development and Diagnostics	29
2.4.2 The Pipeline Problem	31
2.4.3 Biomarkers in the Drug Discovery Process	32
2.4.4 Segmentation of Biomarker Usage	32
2.4.5 Efficacy of Biomarkers as Surrogate Endpoints	33
2.4.6 Biomarkers Used to Reduce the Cost of Drug Development	34
2.4.7 Biomarkers: Challenges and Opportunities	34
2.4.8 Biomarkers in Early Safety and Toxicity Assessment	35
2.4.9 Biomarkers in Determining Validation Parameters	35
2.4.10 Challenges in Development of Biomarkers	36
2.4.11 Using Biomarkers in Early Clinical Development	36
2.4.12 Translational Biomarkers	36
2.4.13 Use of Biomarkers in “Go”/No-Go” Decisions	37
2.4.14 Diagnostic Tests	37
2.4.15 Biomarkers in Deal Making	37
2.4.16 Payors Use Biomarkers in Decision-Making	37
2.5 World Pharmaceutical Markets	38
2.5.1 World Market Summary	38
2.5.2 Company Performance in this Segment	40
2.5.3 Forces Affecting the Structure of the Pharmaceutical Industry	41
2.5.3.1 Threats	41
2.5.3.2 Competitive Forces	42
2.6.1 Industry Overview	42
2.6.1.1 Pharmaceutical Industry Drug Pipeline	44
2.6.1.2 Asia-Pacific to Replace United States and Europe as Pharmaceutical Industry Center	54
2.6.1.3 The Changing Pharmaceutical Business Model	54
2.6.2 Benefits for Companion Diagnostic Tests in Drug Development	55
2.6.3 Strategies for the Creation of Partnerships - Predicting and Overcoming Challenges in Creating Drug Response Profiling Diagnostics	57
2.6.4 Options and Applications	57
2.6.4.1 Clinical Applications of Genomics: The Use of Evidence Based Frameworks by Decision-Makers	57

2.6.5 Challenges, Drivers and Trends	58
2.6.5.1 Macro Trends in Biomarkers	58
2.6.5.2 Biomarkers: Industry SWOT Analysis	61
2.6.6 Breakaway Technologies	62
2.6.7 Collaboration for Companion Diagnostics	63
2.6.8 Key Stake Holders in Companion Diagnostics	63
2.9 Future Developments	65
3. Biomarker Development Tools	66
3.1 New Technologies in Functional Genomics	66
3.1.1 Genomics-Derived Drug Pipeline	66
3.1.2 Future of Genomics Technologies for Drug Target Identification	66
3.2 Overview of Microarrays	67
3.2.1 General Theory of Microarrays	68
3.2.2 GeneChip Probe Array Technology	69
3.2.3 DNA Microarrays	69
3.2.3.1 DNA Microarray Market Size	71
3.2.3.2 DNA Microarrays in SNP Analysis	72
3.2.3.3 DNA Microarrays in Cancer	72
3.2.4 Protein Microarrays	73
3.2.4.1 Reasons Why Researchers Use Protein Microarrays	74
3.2.4.2 Factors for Adoption of Protein Microarrays Technology	74
3.2.4.3 Future Innovations in Protein Microarray Technology	74
3.2.5 New Technologies	75
3.2.5.1 Antibody Microarrays	75
3.2.5.2 Peptide Microarrays	75
3.2.5.3 Peptide MHC Microarrays	75
3.2.5.4 Tissue Microarrays	75
3.2.5.5 Key Points for Developing Microarray Based Applications	76
3.2.5.6 Reasons Why Researchers use DNA Microarrays	77
3.2.5.7 Factors for Difficulties Applying DNA Microarrays Technology	77
3.2.5.8 Emerging Microarray Trends	78
3.2.5.9 Emerging Microarray Applications	78
3.2.5.10 Key Findings on Use of Microarrays	79
3.2.5.11 Advantages and Drivers of Microarrays	79
3.2.5.12 Limitations and Barriers to Use of Microarrays	81
3.2.5.13 qRT-PCR Use in Biomarker Identification and Drug Development	83
3.2.5.14 Microarray Quality Control (MAQC) Project	84
3.3 Theranostics	84
3.3.1 Theranostics in Drug Development	84
3.3.2 Trends in Theranostics	85
3.3.3 Timeline for Impact on Various Segments in Theranostics	85
3.3.4 Challenges for Biomarker Based Therapeutics Development	87
3.4 Pharmaceutical Development and Bioanalytical Services	88
3.4.1 Wyeth Singulex's Erenna	88
3.5 Metabolomics in Drug Discovery	88
3.6 Bioinformatics	90
3.6.1 Definition and Role of Bioinformatics	90
3.6.2 Bioinformatics Sector Overview	93
3.6.3 Future Status of Bioinformatics	93
3.6.3.1 Future in Drug Discovery	93
3.6.3.2 Mergers and Acquisitions Could Deter Bioinformatics Growth	94
3.6.3.3 Barriers to Bioinformatics Growth	94
3.6.3.4 Types of Data and Bioinformatics Applications	94
3.6.3.5 Validated Core Modeling Technology	95
3.6.3.6 Applicability of Bioinformatics for Biomarker Discovery	95

3.6.3.7 Biomarker Data Management Compliant with Industry Standards	96
3.6.3.8 Data Management for Biomarkers	96
3.6.3.8.1 Data Transformation for Biomarker Development	96
3.6.3.8.2 Biomarker Data Collaboration	96
3.6.3.8.3 Interface for Online Data Sources for Genomic Structures	96
3.6.3.8.4 Target Markets for Informatics Software	96
3.6.3.8.5 Bioinformatics Drivers and Challenges in the Pharmaceutical Industry	97
3.6.3.8.6 Products of Bioinformatics	100
3.6.3.8.7 Informatics Tools and Functionalities	101
3.6.3.8.8 Bioinformatics in Lead Identification and Optimization	101
3.6.3.8.9 Bioinformatics in Drug Development and Formulation	102
3.6.3.8.10 Role of Bioinformatics in the Drug Discovery Value Chain	102
3.6.3.8.11 Bioinformatics Software for Drug Discovery and Biomarker Development	102
3.6.3.8.12 Bioinformatics Services	104
3.7 Biomarkers and Proteomics	105
3.7.1 Scientific Background	105
3.7.2 Applying Proteomics to Biomarker Discovery	106
3.7.2.1 Challenges Facing Biomarker Developers	106
3.7.3 Limitations of Proteomic Approaches to Biomarker Discovery	108
3.7.4 Validation of Biomarkers Using LC-MS/MS Systems	109
3.7.5 Use of Mass Spectrometry in Biomarker Discovery	109
3.7.5.1 Multiple Reaction Monitoring Assays (MRMs)	110
3.7.5.2 Gel-based Approaches	110
3.7.5.3 Non-Gel-based Approaches	111
3.7.5.4 SELDI-TOF MS	111
3.7.5.5 SELDI and Prognosis	112
3.7.5.6 SELDI and Treatment Monitoring	112
3.7.5.7 Limitations of Mass Spectroscopy	112
3.7.6 Partnerships for Developing Proteomic Biomarkers	114
3.7.7 Proteomics in Developing a New Cancer Marker	114
3.7.7.1 Translating Proteomic Oncology Discoveries to the Clinic: Development of Analytical Reference Materials, Reagents, Data, and Technology Assessment and Validation	115
3.7.7.2 Challenges of Discovering and Validating Clinical Protein Biomarkers	115
3.7.7.3 Importance of Proteomics in Biomarker Discovery	115
3.8 Toxicogenomics	115
3.8.1 Toxicogenomics Concerns in Drug Safety Data	116
3.8.2 Toxicogenomics and Prioritization of Drug Candidates	116
3.8.3 Genomic Biomarkers for Drug-Induced Nephrotoxicity	117
3.8.4 Use of Biomarkers of Drug-Induced Cardiotoxicity	117
3.8.5 Use of Biomarkers of Drug-induced Hepatotoxicity	117
3.8.6 Transgenic Biomarkers for Adverse Drug-Drug Interactions	117
3.8.7 Challenges to Toxicogenomics	118
3.8.8 The Future Use of Toxicogenomics in Drug Discovery	118
4. Market for Biomarkers in Drug Development	119
4.1 C-KIT (CD117) Expression	122
4.2 CCR5 -Chemokine C-C Motif Receptor	122
4.3 CYP2C19 Variants	123
4.4 CYP2C9 Variants	123
4.5 CYP2D6 Variants	124
4.6 CYP2D6 Variants with Alternate Context	124
4.7 Clinical Biomarkers	124
4.8 Targeting Kidney Toxicity	125
4.8.1 Proximal and Distal Tubular Injury (alpha-GST & Pi-GST)	125
4.8.2 Collecting Duct and Loop of Henle Injury (RPA-1 and RPA-2)	126
4.8.3 Glomerular Injury (Collagen IV)	126

4.8.4 KIM-1	126
4.9 Targeting Hepatotoxicity	127
4.9.1 Breast Cancer	128
4.9.2 Colorectal Cancer	128
4.9.3 Prostate Cancer	128
4.9.4 Cystic Fibrosis	128
4.10 Biomarker Application in Oncology Clinical Development	128
4.10.1 Specific Example of Companion Biomarkers in Clinical Oncology	135
4.10.2 Integration of a Companion Diagnostic Strategy into Oncology Drug Development	135
4.10.2.1 Lilly to Co-Develop Companion IVDs for Cancer Drugs	135
4.10.2.2 Celera to Work on Companion Diagnostics for Merck Cancer Drugs	136
4.10.2.3 BioMérieux to Develop Companion Test for Ipsen's New Breast Cancer Drug	136
4.10.2.4 Perlegen and Roche's 454 Develop Companion Tests	136
4.10.2.5 Ventana Medical Systems and the Critical Path Institute	136
4.10.2.6 Biomarkers in Recentin/AZD 2171 Development	136
4.10.2.7 Biomarkers in Development of Iressa	136
4.10.2.8 Epigenomics' Methylation Biomarker Septin	136
4.11 Targeting Diabetes Related Heart Disease	137
4.12 Key Challenges and Opportunities in Developing Targeted Therapeutics	137
5. Imaging Biomarkers in Drug Discovery	138
5.1 Introduction	138
5.1.1 Validation of Imaging Biomarkers	138
5.1.2 Types of Imaging Used in Drug Development	138
5.1.3 Development of Imaging Technologies	139
5.2 Molecular Imaging	139
5.2.1 Use in Drug Discovery	139
5.2.2 Use in Clinical Applications	139
5.2.3 Use in Clinical Trials	139
5.2.4 Cell-based Screening Technologies in Drug Development	139
5.2.5 Optical Biomarkers	140
5.3 Magnetic Resonance Imaging	140
5.4 Positron Emission Tomography	140
5.5 FDG-PET Patient Phase I Studies	141
5.6 Imaging Biomarkers as Study Endpoints	142
5.6.1 Oncology	142
5.6.2 Parkinson's Disease	142
5.6.3 Cardiac Disease	142
5.7 IT Solutions for Imaging Biomarkers in Biopharmaceutical Research and Development	144
6. Clinical Biomarkers Improving Trial Design	145
6.1 Strategies to Improve the Measurement of Biomarkers for Drug Trials	145
6.2 Key Opportunities in Biomarker Discovery, Development and Commercialization	145
6.2.1 Contract Research Companies	145
6.3 What Strategies Help Translate Biomarkers from Preclinical to Clinical Development?	147
6.4 How Should Biomarker Data Be Compared to "Traditional" Safety and Efficacy Data?	147
7. Biomarkers as Surrogate Endpoints	148
7.1 What is a Surrogate Endpoint?	148
7.2 Benefits and Drawbacks of Surrogate Endpoints	148
7.2.1 Benefits	148
7.2.2 Drawbacks	148
7.3 Improving the Efficacy of Clinical Surrogate End Points Using Biomarkers	148
7.4 Surrogate Endpoint Validation	149
7.5 Effective Use of Surrogates	149
7.5.1 FDG-PET as a Surrogate Endpoint in Oncology Studies	149

7.6 Conclusions	149
8. Market Size, Collaborations and Future Directions for Companion Diagnostics in Drug Development	150
8.1 Strategies to Improve the Measurement of Biomarkers for Drug Trials	150
8.1.1 Key Opportunities in Biomarker Discovery, Development and Commercialization	150
8.1.2 The Rationale Behind Biomarker Strategy	150
8.1.3 New Development Strategies and Their Implications for Deal Making	151
8.1.4 How Biomarkers Are Being Used To Reduce Attrition in Development	151
8.1.5 Combined Therapeutics and Diagnostics Biomarker Business Makes Sense	152
8.1.6 Use of Biomarkers In House or Partner with a Diagnostics Company	152
8.2 What is the Best Balance of Resources to Have the Most Efficient Pathway to Develop Biomarkers?	152
8.3 Current and Future Trends in Drug Development	152
8.4 Future Role of Biomarkers in Healthcare	153
8.5 What are the Current Organizational Obstacles in Biomarker Implementation?	154
9. Regulatory Issues for Biomarkers in Drug Development	155
9.1 Introduction	155
9.1.1 Role of Regulatory Agencies in Development of Biomarkers	156
9.2 FDA Perspective of Biomarkers in Clinical Trials	156
9.2.1 FDA as a Gatekeeper of Companion Biomarkers	156
9.2.2 FDA Criteria for a Valid Biomarker	157
9.2.3 FDA Product Submission and Review Process	158
9.2.4 FDA Pipeline for Biomarker Tests	158
9.2.5 Adaptive Clinical Trial Design	159
9.2.6 Orphan Drug Act and Biomarkers: Options and Opportunities	159
9.3 Role of StART-PCR™ in Increasing Value of Pharmacogenomic Data	160
9.4 Supporting IND, NDA, and BLA Submissions	161
9.5 Performance Characteristics of Biomarker Tools	163
9.6 Biomarker Initiative and VGDs	164
9.7 Biomarker Qualification Pilot Process at the FDA	165
9.7.1 Introduction	165
9.7.2 Biomarker is Validity	166
9.7.3 Biomarker Qualification Process Map	166
9.7.4 Biomarker Qualification Pilot Process	166
9.7.5 The Pipeline Problem	168
9.7.6 FDA Critical Path	169
9.7.6.1 Challenge and Opportunity on the Critical Path to New Medical Products	170
9.7.6.2 The NIH Roadmap	171
9.7.6.3 Predictive Safety Testing Consortium	171
9.7.7 Negotiating the Critical Path	171
9.7.8 Technical Dimensions along the Critical Path	172
9.7.9 Product Development Toolkit	173
9.7.10 Tools for Assessing Safety	174
9.7.11 Tools for Demonstrating Medical Utility	176
9.7.12 Tools for Manufacturing	179
9.7.13 Orphan Products Grant Program	179
9.7.14 Slowdown in New Medical Products	180
9.7.15 Factors Contributing to the Decline in New Product Applications	182
9.7.16 Factors that Cause Unnecessary Delays in New Product Approvals	184
9.7.17 Reducing Avoidable Delays in Time to Approval	186
9.7.18 Reducing Delays in Medical Device Reviews	187
9.7.19 Reducing Delays in Animal Drug Reviews	187
9.7.20 Quality Systems Approach to Medical Product Review	187
9.7.20.1 Instituting Quality Systems in Review of New Drugs and Biologics	188
9.7.20.2 Implementing of the Common Technical Document (CTD) and the electronic CTD	189
9.7.20.3 Implementing Medical Device Quality Initiatives	189

9.7.21 Case Study: Nephrotoxicity Biomarkers	189
9.7.22 Role of the FDA	189
9.8 CMS Regulatory Responsibilities	190
9.9 Role of National Institute of Standards and Technology in Validation of Biomarkers	191
9.10 Biomarkers and FDA's Voluntary Genomic Data Submission	191
9.11 Federal Health Oncology Biomarker Qualification Initiative	193
9.12 Orphan Drug Act and Pharmacogenomics: Options and Opportunities	194
9.13 Post-market Covigilance Programs	195
9.14 Technology Options, Potential Diagnostic Partners and Regulatory Hurdles	196
9.15 What Regulatory Guidance Is Needed for Companion Biomarkers?	197
9.16 U.S. Patent and Trademark Office (USPTO)	198
9.17 IRB Approval in Clinical Trials	198
10. Business Decisions Using Companion Biomarkers in Drug Development	199
10.1 Advantages of a Pharmacogenomic Assessment of Biomarkers to Determine Clinical Dose	199
10.2 Key Opportunities in Biomarker Discovery, Development and Commercialization	199
10.3 What Are the Current Obstacles in Biomarker Implementation?	199
10.4 How Do Business Strategies, Such as Those Relating to Acquisition, Drive Biomarker Strategies?	200
10.5 What is the Right Balance Between Using External Partnerships and Developing Internal Infrastructure?	200
10.6 How Might Novel Biomarker Development Lead to Acquisition Strategies and Their Implications For Deal Making?	200
10.7 Which Types of Biomarkers Should Be Developed at Various Stages in the Drug Pipeline?	200
10.8 What Strategies Help Translate Biomarkers From Preclinical to Clinical Development?	200
10.9 In What Class of Drugs Is the Value of Using Biomarkers in Decision Making the Highest?	201
10.10 Increased Clinical Trial Costs in Targeted Phase I Trials	202
10.11 How Can Big Pharma Co-develop Biomarkers in a Cost-sharing Model for Regulatory Acceptance?	202
10.12 How Are Biomarkers Being Used to Reduce the Attrition Rate in Drug Development?	202
10.13 How Is ROI Measured Using Biomarkers in Drug Development?	202
10.14 How Might Organizational Structures Limit the Use of Biomarkers in Drug Development and How Should R&D Organizations Address This Problem?	202
10.15 How to Maximize Business Development through Biomarker Strategies	203
10.16 What Is the Best Type of Business Model for Developing Biomarkers?	203
10.17 What Are Organizational Impediments Limiting the Use of Biomarkers in Drug Development?	203
10.18 What Are Internal Capabilities for Novel Biomarker Development and Application?	203
10.19 How Can Key Biomarker Technical Expertise Be Applied Across a Complex and Highly-Stratified R&D Value Chain?	204
10.20 At What Stage of Drug Development Have Biomarkers Provided the Most Benefit?	204
10.21 What Companies Are the most Innovative in Development of Biomarkers?	204
10.22 Best Values for Biomarkers in Drug Development and in Diagnostics	204
10.23 Companion Biomarkers Can Increase Value in an Associated Drug	205
11. Company Profiles	206
11.1 Abbott Laboratories	206
11.2 Accelrys	207
11.3 Affymetrix	208
11.4 Agilent Technologies	211
11.5 Amgen	213
11.6 Ananomouse	214
11.7 Applied Maths	215
11.8 Ariadne Genomics	215
11.9 ArrayIt (Integrated Media Holdings)	215
11.10 AstraZeneca	216
11.11 AutoGenomics	217
11.12 Axontologic	217
11.13 Beckman Coulter	218
11.14 BD	224

11.15 Bender MedSystems	225
11.16 Bioalma	225
11.17 BioAnalytics Group	226
11.18 BioCat GmbH	226
11.19 Biocept	226
11.20 BioChain	226
11.21 BioData	227
11.22 BioDiscovery	227
11.23 BioForce Nanosciences	227
11.24 BioGenex	228
11.25 Bioinformatics Solutions	228
11.26 Biomax Informatics	228
11.27 BioMérieux	229
11.28 Biomind	229
11.29 Bio-Rad Laboratories	229
11.30 Biosite	230
11.31 BioSystems International	230
11.32 Biotrin	230
11.33 BioWisdom	230
11.34 Bristol-Myers Squibb Company	231
11.35 Caliper Life Sciences	232
11.36 Caprion Proteomics	235
11.37 Carestream Health	237
11.38 Celera	237
11.39 Cepheid	239
11.40 Chang Bioscience	241
11.41 Clontech Laboratories	241
11.42 CombiMatrix	241
11.43 Compugen	243
11.44 Corimbia	244
11.45 Covance	244
11.46 Cybrdi	244
11.47 CyVera	244
11.48 Dako A/S	244
11.49 Decodon	245
11.50 Definiens	245
11.51 DiagnoSwiss	246
11.52 Discerna	246
11.53 DNAStar	246
11.54 DNATools	246
11.55 Eidogen-Sertanty	247
11.56 Electric Genetics	247
11.57 Eli Lilly and Company	247
11.58 Entelos	248
11.59 ePitope Informatics	248
11.60 Eurogentec	248
11.61 Exiqon A/S	249
11.62 Forensic Bioinformatics	249
11.63 Fujitsu	249
11.64 Future Diagnostics	250
11.65 Genaissance Pharmaceuticals	250
11.66 Gene Codes	250
11.67 Genedata	250
11.68 GeneGo	250
11.69 Gene Network Sciences	251
11.70 Geneva Bioinformatics	251

11.71 Genomatica	251
11.72 Genomic Solutions	251
11.73 Genomining	252
11.74 Gen-Probe	252
11.75 GE Healthcare	256
11.76 GeneStudio	256
11.77 Genomatix Software	256
11.78 GenomeQuest	257
11.79 Genus BioSystems	257
11.80 Genzyme	257
11.81 Geospiza	258
11.82 GlaxoSmithKline	259
11.83 Golden Helix	259
11.84 Grace Bio-Labs	260
11.85 Gyros AB	260
11.86 HealthCare IT	260
11.87 High Throughput Genomics	260
11.88 Human Genome Sciences	261
11.89 Illumina	261
11.90 Imgenex	264
11.91 Imaxia	264
11.92 INCOGEN	264
11.93 Incyte	265
11.94 InforSense	265
11.95 Ingenuity Systems	265
11.96 InPharmix	266
11.97 Insightful Corporation	266
11.98 Integromics, S.L	266
11.99 IBM	266
11.100 IO Informatics	267
11.101 Ipsen	268
11.102 Jerini AG	268
11.103 Johnson & Johnson	268
11.104 Koda Technology	269
11.105 KOOPrime	269
11.106 Life Technologies Corporation	269
11.107 LINCO Research	270
11.108 Luminex	270
11.109 Marligen Biosciences	271
11.110 Matrix Science	271
11.111 MDS	272
11.112 Merck & Company	272
11.113 Merck KGaA	273
11.114 Meso Scale Discovery	273
11.115 Metabolon	274
11.116 Microbionix	274
11.117 MicroDiscovery	274
11.118 Millennium Pharmaceuticals	275
11.119 Millipore	275
11.120 MiraiBio	276
11.121 Molecular Connections	276
11.122 MolMine AS	276
11.123 Molsoft	277
11.124 Monogram Biosciences	277
11.125 MTR Scientific	278
11.126 Multimetrix	278

11.127 Nanogen	278
11.128 Nanosphere	280
11.129 NetGenics	280
11.130 NextGen Sciences	280
11.131 NimbleGen Systems	281
11.132 Nonlinear Dynamics	281
11.133 Novartis	281
11.134 Nuvera Biosciences	282
11.135 Ocimum Biosolutions	282
11.136 OmniViz	282
11.137 One Lambda	282
11.138 Oracle	283
11.139 Ore Pharmaceuticals	284
11.140 Orla Protein Technologies	285
11.141 Osmetech	285
11.142 Oxonica	285
11.143 PamGene BV	286
11.144 Panomics	286
11.145 Partek	286
11.146 Pepscan	287
11.147 Perbio Science	287
11.148 Perlegen Sciences	287
11.149 Pfizer	287
11.150 PharmaSeq	288
11.151 Pierce Biotechnology	288
11.152 Platypus Technologies	288
11.153 Predictive Patterns Software	288
11.154 Proceryon	288
11.155 Protagen AG	289
11.156 ProteinOne	289
11.157 Proteome Sciences	289
11.158 PubGene	289
11.159 Qiagen	290
11.160 Radix BioSolutions	293
11.161 Radox Laboratories	294
11.162 RayBiotech	294
11.163 Redasoft	294
11.164 RedStorm Scientific	294
11.165 Reel Two	294
11.166 Rescentris	295
11.167 Roche	295
11.168 Rosetta Biosoftware	296
11.169 Rules-Based Medicine	296
11.170 SAS	296
11.171 Schleicher & Schuell BioScience	297
11.172 SciTegic	297
11.173 Semantx Life Sciences	297
11.174 Sequenom	297
11.175 Sigma-Aldrich	298
11.176 Silicon Genetics	299
11.177 Singulex	299
11.178 Softberry	299
11.179 SoftGenetics	299
11.180 SomaLogic	299
11.181 Spotfire	300
11.182 SPSS	300

11.183 Strand Life Sciences	301
11.184 Stratagene	301
11.185 SuperBioChips Laboratories	301
11.186 SurroMed	301
11.187 Sun Microsystems	301
11.188 Sygnis Pharma AG	302
11.189 Techne Corporation	302
11.190 Tepnel Life Sciences	303
11.191 Teranode	303
11.192 Textco BioSoftware	303
11.193 TG Services	304
11.194 Thermo Fisher Scientific	304
11.195 Third Wave Technologies	305
11.196 TIBCO Software	305
11.197 TimeLogic	305
11.198 TriStar Technology Group	305
11.199 Tyrian Diagnostics (formerly Proteome Systems)	306
11.200 VBC-Genomics Bioscience Research GmbH	306
11.201 Ventana Medical Systems	306
11.202 ViaLogy	307
11.203 Wyeth	307
11.204 Zeptosens	307
11.205 Zeus Scientific	308
11.206 Zyagen	308
Appendix 1: FDA Guidance for Industry: Pharmacogenomic Data Submission	309
A 1.1 Introduction	309
A 1.2 Background	309
A 1.3 Submission Policy	310
A 1.3.1 General Principles	310
A 1.3.2 Specific Uses of Pharmacogenomic Data in Drug Development and Labeling	311
A 1.3.3 Benefits of Voluntary Submissions to Sponsors and FDA	312
A 1.4 Submission of Pharmacogenomic Data	313
A 1.4.1 Submission of Pharmacogenomic Data during the IND Phase	313
A 1.4.2 Submission of Pharmacogenomic Data to a New NDA, BLA, or Supplement	314
A 1.4.3 Submission to a Previously Approved NDA or BLA	315
A 1.4.4 Compliance with 21 CFR Part 58	315
A 1.4.5 Submission of Voluntary Genomic Data from Application-Independent Research	316
A 1.5 Format and Content of a VGDS	316
A 1.6 Process for Submitting Pharmacogenomic Data	317
A 1.7 Agency Review of VGDSs	317

Glossary 319

INDEX OF FIGURES

Figure 2.1: Drug Discovery and Development Paradigm	24
Figure 2.2: Paradigm of Drug Discovery and Development Illustrating the Central and Essential Role of Biomarkers in Screening	25
Figure 2.3: Functional Genomic Process for Drug Development	26
Figure 2.4: Reimbursement for Diagnostics in Healthcare Decision Making	30
Figure 2.5: Market Growth and Evolution of Companion Biomarkers	31
Figure 2.6: Medical Product Development Models	32
Figure 2.7: Segmentation of the Biomarker Development Market	33
Figure 2.8: Medical Research in the U.S. Outpaces the Rest of the World	45

Figure 2.9: Worldwide Pharmaceutical Products Markets	48
Figure 2.10: Biomarkers Market Drivers	58
Figure 2.11: Challenges in the Biomarkers Space	59
Figure 2.12: FDA Co-Developed Products	64
Figure 3.1: Informatics Applications Along the Drug Discovery Value Chain	91
Figure 3.2: Bioinformatics Software Flow Chart	91
Figure 3.3: Growth of GenBank, 1982 - 2008	92
Figure 3.4: Role of Bioinformatics in the Drug Discovery Value Chain	102
Figure 3.5: Challenges in the Study or Utilization of Proteomic Biomarkers	107
Figure 3.6: Challenges in the Study or Utilization of Companion Diagnostic Biomarkers	107
Figure 3.7: Top Unmet Needs in Products in the Biomarkers Space	108
Figure 4.1: Growth and Evolution of the Biomarker Space	120
Figure 4.2: Revenue Forecast Projections for Global Biomarker Markets by Segments, 2005 - 2012	121
Figure 4.3: Biomarker Discovery by Therapeutic Area	122
Figure 4.4: Kidney Biomarker Paradigm	125
Figure 4.5: Hepatic Biomarker Paradigm	127
Figure 9.1: IPRG Biomarker Qualification Process	167
Figure 9.2: Critical Path for Drug Development	180
Figure 9.3: Path for R&D Product Development	181
Figure 9.4: Dimensions of the Critical Path	181
Figure 9.5: FDA Interactions During Drug Development	182
Figure 9.6: Problem Resolution During the FDA Review Process	182
Figure 9.7: VGDS Process Flow	193
Figure 10.1: Discovery, Validation and Use of Biomarkers	201

INDEX OF TABLES

Table 2.1: Utility of Biomarkers as Companion Diagnostics to Drug Development	20
Table 2.2: Biomarker End Points in Drug Development	22
Table 2.3: Value of Biomarkers in Phase II Clinical Trials	24
Table 2.4: Comparative Genome Sizes of Humans and Other Organisms	27
Table 2.5: Global Pharmaceutical Drug Sales, 2004 - 2012	38
Table 2.6: Worldwide Generic Pharmaceutical Drug Market, 2003 - 2012	39
Table 2.7: Worldwide OTC Pharmaceutical Drug Market, 2003 - 2012	39
Table 2.8: Worldwide Biopharmaceutical Drug Market, 2003 - 2012	40
Table 2.9: Top Ten Pharmaceutical Companies by Worldwide Sales, 2008	40
Table 2.10: Pharmaceutical Companies' Drug Sales as Percent of the Worldwide Market, 2008	41
Table 2.11: Threats to Pharmaceutical Industry Productivity	42
Table 2.12: Competitive Forces Governing the Pharmaceutical Industry	42
Table 2.13: Time Line for Development of Companion Diagnostics	43
Table 2.14: Leading Therapy Classes for R&D, 2008	44
Table 2.15: Global Pharmaceutical Industry R&D Spending, 1995 - 2008	46
Table 2.16: Pharmaceutical R&D Expenditures by World Region, 1990 - 2006	46
Table 2.17: U.S. Government NIH Research Budget, 1995 - 2008	47
Table 2.18: Pharmaceutical Companies Ranked by Total R&D Expenditures, 2006	47
Table 2.19: Global Pharmaceutical Sales by Region, 2007	48
Table 2.20: World's Top-Selling Drugs, 2007	49
Table 2.21: Top Pharmaceutical Companies by Healthcare Revenue, 2008	50
Table 2.22: Leading Therapy Classes by Global Pharmaceutical Sales, 2007	50
Table 2.23: Leading Ten Therapeutic Classes by U.S. Sales, 2003, 2006 and 2007	50
Table 2.24: Top Ten Therapeutic Classes by U.S. Dispensed Prescriptions, 2006 and 2007	51
Table 2.25: Top Ten Brand Drugs by Retail Dollars, 2007	51
Table 2.26: Pharmaceuticals Industry Challenges	54
Table 2.27: Reasons for Developing Phase I Biomarkers	55
Table 2.28: Percentage of Non-Responders in Various Drug Classes	56

Table 2.31: High Profile Drug Withdrawals from the Marketplace	56
Table 2.30: Market Opportunities in Biomarkers	59
Table 2.31: Challenges for Market Adoption of the Various Biomarkers Tests	60
Table 2.32: Biomarkers Industry SWOT	62
Table 3.1: Worldwide Microarray Market Size, 2004 - 2012	71
Table 3.2: List of DNA Array Manufacturers	78
Table 3.3: U.S. qRT-PCR Market, 2007 - 2013	84
Table 3.4: Theranostics Technology Platforms—Timeline of Impact	85
Table 3.5: Impact of Personalized Medicine on Various Therapeutic Areas	86
Table 3.6: Hurdles in Biomarkers Development in Therapeutic Areas	87
Table 3.7: Data Source and Bioinformatic Investigations	95
Table 3.8: Drivers and Challenges of the Bioinformatics Industry	98
Table 3.9: Bioinformatics Activities, Sub-Activities and Key Players	104
Table 3.10: Concentration of Some Abundant Proteins, New Cancer Biomarkers Identified by SELDI-TOF, and Classical Cancer Biomarkers in Serum	113
Table 3.11: Device Submission Elements for the FDA	113
Table 3.12: Toxicogenomic Standards and Their Organizations	117
Table 3.13: Genomic and Proteomic Technologies	118
Table 4.1: Companion Biomarker Market Size, 2008 - 2013.	119
Table 4.2: Kidney Biomarkers	126
Table 4.3: Herceptin Worldwide Sales, 1999 - 2007	129
Table 4.4: Characteristics of Different Cancer Biomarker Types and Associated Market Opportunities	130
Table 4.5: Segmentation of the Cancer Biomarker Market by Type of Cancer Biomarkers and Market Size	131
Table 4.6: Cancer Biomarker Market Estimates by Tissue of Origin	132
Table 4.7: Companies Developing New Proteomic Cancer Biomarker Technology Platforms	133
Table 4.8: Cancer Biomarkers Used to Maximize Likelihood of Response	134
Table 4.9: Biomarkers for Monitoring Therapeutic Effectiveness and Resistance	135
Table 6.1: Contract Research Companies	146
Table 8.1: Stakeholders in Biomarker Development	154
Table 9.1: Structure of the Critical Path	172
Table 9.2: Device Submission Elements for the FDA	184

1. Overview

1.1 Statement of Report

The term “companion biomarker” means that a particular diagnostic test is specifically linked to a therapeutic drug either in drug development or in the clinic. This linkage can be an important component of the drug development process; or alternatively, the companion biomarker can be useful in ameliorating the regulatory process for the drug, or acting as an aid to therapeutic use in the clinic. This analysis focuses on the role of companion diagnostic tests in drug development.

This report will provide an in-depth discussion and analysis of the application of companion biomarkers to drug development and targeted therapeutics, as well as their use in clinical trials and the regulatory forum. This examination emphasizes new and developing technology platforms meant to aid in development of drugs for therapeutic use, and sometimes to be available as companion tests for these drugs in the clinic.

1.2 About This Report

This report describes new biomarker technology platforms developed for the analyses of drug targets that are connected to the effectiveness of therapeutic agents in a clinical setting. The emphasis is on those companies that are actively developing and marketing new companion diagnostic tests for performing biomarker tests during drug development, as opposed to the more routine and clinically accepted companion markers that are manufactured and marketed by large diagnostic companies for routine clinical use.

This review focuses on biotech and pharmaceutical companies who have new products and procedures for drug development. Traditional diagnostic companies in the process of developing new ideas for clinical diagnostic purposes are not reviewed in any detail here. However, many pharmaceutical companies take great pains to point out that they are not diagnostic development companies, and as new drugs reach the clinic, some of the companion diagnostic tests that are used internally by pharmaceutical companies in their clinical trials and FDA applications can be turned over to diagnostic companies for further development in the clinic.

1.3 Scope of the Report

This analysis differs from TriMark’s *Personalized Medicine and Companion Diagnostics for Personalized Medicine and Cancer Therapy* reports in that it emphasizes diagnostic tests that are linked in their usage to development stage work on therapeutic agents. This study emphasizes pharmaceutical and biotech companies that are actively developing new technology platforms for performing companion biomarker diagnostics tests in the clinical trial and early drug development setting.

1.4 Objectives

The main objectives of this review are:

- Identifying viable technology drivers through a comprehensive look at platform technologies for *in vitro* diagnostic tests used as biomarkers, which are used to monitor the efficacy of therapeutic drugs.
- Obtaining a complete understanding of the new companion biomarker diagnostic tests—*i.e.*, predictive, screening, prognostic, monitoring, pharmacogenomic and theranostic—from their basic principles to their applications.
- Discovering growing market opportunities in drug development by identifying high-growth applications in different biomarker areas, with a major focus on the biggest and expanding markets in oncology (*e.g.*, biomarkers for cancer therapeutics).
- Focusing on global pharmaceutical industry development through an in-depth analysis of the major world markets for companion diagnostics, including growth forecasts.

The report discusses the various market trends and opportunities using biomarkers in drug development. The reader should consult other TriMark Publications reports at <http://www.trimarkpublications.com> for detailed discussions of important individual market segments related to the companion diagnostics market, such as *Clinical Chemistry*

Testing, High-Growth Diagnostic Test Markets, Blood Glucose Testing and Diabetes Management, Over-The-Counter Diagnostic Testing Markets and Point of Care Testing. TriMark provides a separate market report called *DNA Sequencing and PCR Markets*, which emphasizes the analytical methods and PCR technology platforms used in companion diagnostics. TriMark also publishes a separate report on routine clinical tumor markers in current use and their markets: *Cancer Diagnostic Testing World Markets*. A sister report, *Pharmacogenomics for Clinical Use*, on the use of companion diagnostic tests in treatment selection for patients in the diagnostic sector is recommended as a companion report to this one. The biotech sector developing new companion biomarkers for drug development is the focus of this examination.

Specialty companion diagnostics testing such as pathology screening methods and special tissue stains to examine companion cells *in situ* are mentioned, since they are often part of the overall analytical focus of companies that market companion technology platforms. However, no effort is made to quantify this older and broader market. These subjects are discussed in other TriMark Publications reports. Leading companies are discussed in-depth, with sections on the companies' histories, product lines, business and marketing analyses, and subjective commentary on the companies' market positions.

The report examines:

- Opportunities and hurdles in the development of companion biomarkers in drug discovery using proteomics and genomics.
- Secreted proteins as biomarkers.
- Adaptive design using biomarkers.
- Pharmacodynamic biomarkers identified with broad-based phenotyping as companion diagnostics.
- Tools for improving measurement, safety and validation of biomarkers in drug development.
- Filling the gap between discovery and clinically validated biomarkers.
- Enabling technologies for oncology biomarker discovery.

This analysis answers the questions:

- How can pharmaceutical companies identify which agents need to be developed with a companion diagnostic and which do not?
- Is the stratification of disease markets a reason to avoid targeted therapies and companion diagnostics?
- Which diagnostics' companies are developing biomarkers that might be potential targets for licensing or acquisition?
- What are the latest developments in the biomarker field with regard to drug development?
- What are the advantages of going the CLIA certified lab route?
- Are all companion diagnostics likely to need FDA approval in the near term?
- Which companies are utilizing cutting-edge technologies to develop, validate, and implement companion biomarkers for clinical use in the drug development and clinical trial setting?
- What impediments still exist to incorporating promising biomarkers into clinical trials?
- Which companion biomarkers show the most promise for use in drug approval?
- How can regulatory oversight drive approval and adoption of new technologies?
- Which alliances show the greatest synergy in bringing valid biomarkers to drug development?
- Which shared technologies are driving the most encouraging development?
- What is the current FDA stance on biomarkers and their potential to increase efficiency in drug development?
- How will insurance companies react to the use of biomarkers for pre-disposition and personalized medicine?
- What is the FDA's Critical Path Initiative?
- Do biomarkers really speed up the approval process?
- What stages does a biomarker need to go through for the FDA to consider it validated?
- What is the FDA viewpoint on pre-competitive cooperation on biomarker studies?
- What are the key opportunities in biomarker discovery, development and commercialization?
- What are the current obstacles in biomarker implementation?

- How do business strategies, such as those relating to acquisition, drive biomarker strategies?
- What is the right balance between using external partnerships and developing internal infrastructure?
- How might novel biomarker development lead to acquisition strategies and their implications for deal making?
- Which types of biomarkers should be developed at various stages in the drug pipeline?
- What strategies help translate biomarkers from preclinical to clinical development?
- In what class of drugs is the value of using biomarkers in decision making the highest?
- How are clinical trial costs increased by including biomarkers?
- How can Big Pharma co-develop biomarkers in a cost-sharing model for regulatory acceptance?

Key features of this report:

- Analysis of leading pharmaceutical and biotechnology companies and academic groups at the forefront of biomarker discovery, validation and utilization.
- Examination of the key trends which are currently affecting the discovery and application of biomarkers such as the development of molecular diagnostics and the application of valid, probable valid and exploratory biomarkers in drug discovery.
- Assessment of the pivotal role that biomarkers play in the development of new diagnostic devices both in conjunction with drugs as targeted therapies and in areas of unmet medical need.

1.5 Methodology

The author of this report is a Ph.D. in biochemistry from the University of Minnesota, with many decades of experience in scientific writing and as a medical industry analyst. He has been a senior director of several large regional and national healthcare laboratories. Company-specific information is obtained mainly from industry trade publications, academic journals, news and research articles, press releases and corporate websites, as well as annual reports for publicly-held firms. Additionally, sources of information include the non-governmental organizations (NGOs) such as the World Health Organization (WHO) and governmental entities like the U.S. Department of Health and Human Services (HHS) and U.S. federal agencies such as National Institutes of Health (NIH), Food and Drug Administration (FDA) and the Centers of Disease Control and Prevention (CDC). Where possible and practicable, the most recent data available have been used.

Some of the statistical information was taken from Biotechnology Associates' databases and from TriMark's private data stores. The information in this study was obtained from sources that we believe to be reliable, but we do not guarantee the accuracy, adequacy or completeness of any information or omission or for the results obtained by the use of such information. Key information from the business literature was used as a basis to conduct dialogue with and obtain expert opinion from market professionals regarding commercial potential and market sizes. Senior managers from major company players were interviewed for part of the information in this analysis.

Primary Sources

TriMark collects information from hundreds of database tables and many comprehensive multi-client research projects, as well as Sector Snapshots that we publish annually. We extract relevant data and analytics from TriMark's research as part of this data collection.

Secondary Sources

TriMark uses research publications, journals, magazines, newspapers, newsletters, industry reports, investment research reports, trade and industry association reports, government-affiliated trade releases and other published information as part of its secondary research materials. The information is then analyzed and translated by the Industry Research Group into a TriMark study. The Editorial Group reviews the complete package with product and market forecasts, critical industry trends, threats and opportunities, competitive strategies and market share determinations.

TriMark Publications Report, Research and Data Acquisition Structure

The general sequence of research and analysis activity prior to the publication of every report in TriMark Publications includes the following items:

- Completing an extensive secondary research effort on an important market sector, including gathering all relevant information from corporate reporting, publicly-available data and proprietary databases.
- Formulating a study outline with the assigned writer, including important items, as follows:
 - Market and product segment grouping, and evaluating their relative significance.
 - Key competitors' evaluations, including their relative positions in the business and other relevant facts to prioritize diligence levels and assist in designing a primary research strategy.
 - End-user research to evaluate analytical significance in market estimation.
 - Supply chain research and analysis to identify any factors affecting the market.
 - New technology platforms and cutting-edge applications.
- Identifying the key technology and market trends that drive or affect these markets.
- Assessing the regional significance for each product and market segment for proper emphasis of further regional/national primary and secondary research.
- Completing a confirmatory primary research assessment of the report's findings with the assistance of expert panel partners from the industry being analyzed.

1.6 Executive Summary

Key Findings:

- The biomarker market is a relatively new market and is forecast to quadruple to around \$ [REDACTED] by [REDACTED] from just over \$ [REDACTED] in [REDACTED], boosted primarily by growth in proteomics and metabonomics biomarker discovery.
- The application of pharmacogenomics to targeted studies, in which patient populations are enriched with potential responders, can lead to cost savings of around \$ [REDACTED] through the streamlining of clinical trials.
- The market for molecular diagnostics is gaining momentum, with Roche's AmpliChip P450 the first to receive regulatory approval. Tests for areas of high unmet need, such as Alzheimer's disease, are set to drive further growth in the market to [REDACTED].
- The role of biomarkers spans all aspects of drug discovery and development from target discovery and validation, lead prioritization and optimization, study of drug and disease mechanisms, toxicity profiling and proof-of-concept in preclinical studies, to use in clinical trials as secondary and surrogate endpoints.
- Biomarkers in drug discovery, development and clinical diagnostics.
- Regulatory acceptance of biomarkers now and in the future.
- Fishing for new drug targets with biomarkers.
- Biomarkers aiding "go"/"no-go" decisions.
- Imaging biomarkers directing clinical dosing studies.
- Clinical biomarkers improving trial design.
- Biomarkers as surrogate endpoints.
- Market size, collaborations and future directions.

The introduction of biomarkers to drug development will help bring new medicines by:

- Identifying the right patients faster.
- Reducing the time of developing new drugs.
- Improving the ability to predict success in drug development.
- Decreasing the attrition rate among developmental candidates.
- Lowering development costs.

- Aiding in monitoring drugs during the regulatory process.
- Bringing greater efficiency to clinical trials.

More recently, biomarkers have begun to assume a greater role in drug discovery and development. The challenge for biomarkers in drug development is to improve the introduction of earlier, more robust drug safety and efficacy measurements into the drug development pipeline. TriMark sees its role in drug development as continuing to grow for the foreseeable future. The world pharmaceutical industry, driven by scientific and technological advances, new drug discoveries, advances in therapeutic knowledge and changes in government and regulatory controls, generally is very successful. The combined global pharmaceutical markets were valued at \$ [REDACTED] in [REDACTED], up [REDACTED] % from [REDACTED]. Global pharmaceutical sales grew at a compounded annual growth rate (CAGR) of [REDACTED] % over the last [REDACTED] years. The pharmaceutical drug sector is projected to reach \$ [REDACTED] worldwide by [REDACTED], with a CAGR of [REDACTED] %.

Though the pharmaceutical industry remains one of the most profitable and stable industries, several variables are threats to continued growth and are causing fundamental changes in the industry structure. The accelerating cost of medical care and, in particular, the escalating cost of drugs (particularly to the elderly) has the drug industry under attack. We believe that this presents a golden opportunity for new technologies in drug development, *i.e.*, biomarkers. The use of companion diagnostic tests (*e.g.*, biomarkers) in drug development will:

- Yield safer and more efficacious drug products.
- Reduce clinical trial and development costs.
- Improve post-marketing safety profiles.
- Salvage therapies that otherwise would not be granted approval.

Biomarkers must have the following operational characteristics to be applicable to drug development programs:

- Readily available source material.
- Minimally invasive.
- Multiple sampling possible.
- Surrogacy: changes in the biomarker are linked to clinical outcomes.

Biomarkers have been used in drug development to establish:

- A minimally biologically effective dose (MBED).
- Optimal biologically effective dose (OBED).
- Selection of optimal dose & schedule for Phase II and Phase III trials.
- Make effective “go”/“no-go” decisions.

Selectivity is an important aspect of biomarker development as companions in drug development:

- Careful selection of targets for clinical trials.
- Careful and deeper analysis of toxicity screening.
- Proper patient selection for late stage trials.
- More data for the FDA.
- Possible companion diagnostic tests for patient selection and efficacy in the clinic.
- Partnering of early stage discovery companies with contract research organizations (CROs) and traditional pharma companies.

In addition, the larger pharmaceutical companies are utilizing biomarkers to look for efficacy or toxicity of their lead compounds in patient subpopulations. The classic example here is screening for HER-2/neu over expression before using the biologic therapeutic Herceptin in breast cancer therapy. Potential benefits of biomarkers as companion diagnostics:

- Streamline drug discovery programs.
- Provide a target for therapy.

- Identify potential responders to a drug.
- Identify individuals at risk for adverse events.
- Tool for monitoring response to drug therapy.

The global market for biomarkers is expected to more than double over the next five years to reach an estimated \$ [REDACTED]. Unlike the diagnostics market, companion diagnostics is much more of a developing market, and user segments in the clinical and drug development space are still diffuse. As such, TriMark feels that the companion diagnostic market is still in its infancy, making it difficult to accurately predict the growth trajectory of this space. Key points noted include the following:

- An initial lag exists as awareness is generated in the clinical marketplace, followed by recruitment of early adopters who generate new applications. This drives early revenue generation in the marketplace and more interest in developing companion diagnostics for clinical trials. For companion diagnostics, this occurred in [REDACTED] to [REDACTED].
- Rapid growth as the broader market is recruited by the initial papers and due to the excitement generated by early adopters. The growth rate of the clinical user market is high as new applications are developed and vendors commercialize products aggressively. The market is beginning to fragment as drug developers begin to routinely add companion tests to their programs; this is the near term outlook for companion diagnostics.
- Despite a slowdown of the growth rate, revenues in the market keep increasing as new products are introduced in the clinic, new applications developed and new clinical trials are recruited. TriMark expects this to continue through [REDACTED] and [REDACTED] for the companion diagnostics marketplace.

Companion Biomarker Trends:

- The relative contribution of therapeutic development and clinical trials using personalized medicine is small; they account for only [REDACTED]% of the total end-user applications.
- The current personalized medicine marketplace is not heavily-weighted towards therapeutic development and clinical trials.
- A large proportion of this marketplace—[REDACTED]% in total—is composed of participants that are involved with developing technologies or products for personalized medicine. The emphasis is more “upstream” in this marketplace, as opposed to more “downstream” applications—such as therapeutics development, conducting clinical trials, etc.
- The industry still does not contain enough molecular signatures which are predictive of biological outcome to create a large supply of companion biomarkers, and this remains a significant market opportunity for the market participants.

Results/Takeaways from the Market Model

The current biomarker market size is estimated at \$ [REDACTED] worldwide, based upon the size of the genomic market. This market opportunity is focused in three spaces: 1) drug development targets, 2) drug development efficacy and 3) clinical end points. Cost per experiment is only for direct cost of the reagents/consumables and does not include salaries, other personnel costs, equipment/instrumentation, or license fees. This market model is highly conservative, and TriMark feels that it appropriately reflects the industry revenues harvested from direct sales of products into the biomarker space. Growth is expected to be [REDACTED]% per year, reaching \$ [REDACTED] by [REDACTED]. Pharma companies are intensely interested in examining the role of biomarkers in:

- Early-stage drug discovery.
- Preclinical studies.
- Late-stage clinical trials of drug development.